Spectrum Pharmaceuticals - SPPI Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPPI shares.
View SPPI analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1 year price targets for Spectrum Pharmaceuticals' stock. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they expect the company's stock price to reach $2.44 in the next twelve months. This suggests a possible upside of 204.6% from the stock's current price.
View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts.

Spectrum Pharmaceuticals' stock was trading at $0.3685 at the beginning of 2023. Since then, SPPI shares have increased by 117.1% and is now trading at $0.8001.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our SPPI earnings forecast.

Spectrum Pharmaceuticals will be holding an earnings conference call on Wednesday, March 22nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. During the same period in the previous year, the firm earned ($0.37) earnings per share.

Spectrum Pharmaceuticals issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10.00 million-$10.00 million, compared to the consensus revenue estimate of $3.82 million.

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.03%), Geode Capital Management LLC (0.80%), Morgan Stanley (0.68%), Millennium Management LLC (0.67%), Renaissance Technologies LLC (0.57%) and CM Management LLC (0.36%). Insiders that own company stock include Francois Lebel, Jeff L Vacirca, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer, Thomas J Riga and William Ashton.
View institutional ownership trends.

Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SPPI stock can currently be purchased for approximately $0.80.

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $162.59 million. The biotechnology company earns $-158,630,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

The company employs 163 workers across the globe.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (702) 835-6300, via email at ir@sppirx.com, or via fax at 702-260-7405.